The ability of Human EGF Neutralizing (D8A1) Rabbit mAb to inhibit hEGF-induced MCF 10A cell proliferation was assessed. MCF 10A cells were treated with increasing concentrations of antibody in the presence of hEGF #8916 (2 ng/ml). After 24 hr, cells were labeled with BrdU for 4 hr and BrdU incorporation was determined using BrdU Cell Proliferation Assay Kit #6813.Learn more about how we get our images
The proliferation of MCF 10A cells treated with increasing concentrations of hEGF #8916 was assessed. After 24 hr, cells were labeled with BrdU for 4 hr and BrdU incorporation was determined using BrdU Cell Proliferation Assay Kit #6813.Learn more about how we get our images
CST recommends incubation of the neutralizing antibody with the intended target for 1 hr at 37ºC before addition to the experiment at an optimal concentration determined by the user.
Lyophilized from a 0.2 µm filtered solution in 10 mM HEPES with trehalose.
Store lyophilized material at -20ºC. After reconstitution, recommended storage at 4ºC for 1 month or -20ºC for 6 months. Avoid repeated freeze/thawing.
Human EGF Neutralizing (D8A1) Rabbit mAb binds to human EGF and neutralizes its effects in an MCF 10A cell proliferation assay. This antibody does not cross-react with human betacellulin or human TGF-α.
Monoclonal antibody is produced by immunizing animals with a recombinant human EGF protein.
Neutralizing antibodies can be used to inhibit normal biological function through their binding to biological molecules. These reagents can be used to determine the effects that a particular molecule has in biological systems. Human EGF Neutralizing (D8A1) Rabbit mAb has been shown to neutralize the EGF-induced proliferation of MCF 10A cells in vitro with an ND50 in the range of 200-700 ng/ml.
<0.1 EU/µg of antibody
EGF is produced by epithelial cells, fibroblasts, and many other cell types (1,2). Low molecular weight soluble EGF is generated through proteolysis of a larger ~130,000 kDa transmembrane precursor (1,2). Both soluble and membrane forms of EGF are active (2). EGF induces proliferation, differentiation, and survival of many cell types including tumor-derived cells (1-3). There are multiple members of the EGF family and multiple members of the HER/ErbB EGF receptor family. EGF binds to HER1/ErbB1 and induces homo- or heterodimerization with other HER/ErbB family members, resulting in signaling through the MAPK, PI3K/Akt, and Stat5 pathways (1). Research studies have implicated EGF, EGF family members, EGF receptors, and their signaling pathways in many cancers (1,2).
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
Explore pathways related to this product.